DEF: Lisata Therapeutics Seeks Stockholder Approval for Director Elections, Stock Plan Amendment, and Auditor Ratification

Lisata Therapeutics is holding its 2025 Annual Meeting of Stockholders to vote on key proposals including the election of directors, an amendment to the Employee Stock Purchase Plan, and the ratification of auditors.

Summary

• Lisata Therapeutics is holding its 2025 Annual Meeting of Stockholders on June 10, 2025, via live webcast.
• Stockholders will vote on the election of two Class III directors, Mohammad Azab and Steven Klosk, for a three-year term expiring in 2028.
• A proposal to amend the 2017 Employee Stock Purchase Plan (ESPP) to increase the number of shares available from 113,333 to 158,333 will be voted on.
• Stockholders will also vote to ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Non-binding advisory votes will be held on executive compensation and the frequency of stockholder advisory votes on executive compensation.
• The Board of Directors recommends voting 'FOR' all proposals.
• The record date for determining stockholders eligible to vote is April 17, 2025.
• Proxy materials are available online and were distributed to stockholders on or about April 25, 2025.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposals are typical for an annual meeting, and the Board recommends voting in favor of all proposals.

Positives

• The company is providing stockholders with the opportunity to vote on key governance matters.
• The proposed amendment to the ESPP could incentivize employees and align their interests with those of stockholders.
• The company is using a virtual meeting format, which may increase accessibility for stockholders.
• The company has a process for stockholders to communicate with the Board of Directors.

Risks

• The advisory votes on executive compensation are non-binding, so the company is not obligated to act on the results.
• The company's success depends on the performance of its executive officers, and any loss of key personnel could negatively impact the company.
• The company operates in a highly competitive industry, and there is no guarantee that it will be able to compete effectively.

Future Outlook

The company is seeking stockholder approval for several proposals that will impact the company's governance and compensation practices.

Management Comments

• On behalf of the board of directors, we thank you for your continued support, stated David J. Mazzo, Ph.D., President and Chief Executive Officer.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including annual meetings, director elections, and executive compensation disclosures.

Comparison to Industry Standards

• The structure of the board with classified directors is a common but not universal practice among public companies.
• The use of independent auditors and the requirement for audit committee oversight are standard practices to ensure financial integrity.
• Executive compensation practices, including base salary, bonus, and equity awards, are typical components of compensation packages in the biopharmaceutical industry.
• The inclusion of say-on-pay proposals aligns with regulatory requirements and allows stockholders to express their views on executive compensation.
• The company's equity compensation plans are similar to those offered by other companies in the industry to attract and retain employees.

Stakeholder Impact

• Stockholders will have the opportunity to influence the company's governance and compensation practices through their votes.
• Employees may benefit from the proposed amendment to the ESPP, which could increase their ownership stake in the company.
• The outcome of the proposals could impact the company's financial performance and long-term success, which would affect all stakeholders.

Next Steps

• Stockholders need to review the proxy materials and vote on the proposals before the Annual Meeting on June 10, 2025.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Director Election, Employee Stock Purchase Plan, Executive Compensation, Auditor Ratification, Lisata Therapeutics, Governance